Analyst Jill Wu Raises Target Price and Reiterates Buy on Innovent Biologics After Strong 1H26 Beat and Robust Growth Outlook
Tip Ranks·- CMB International Securities analyst Jill Wu maintained a Buy rating on Innovent Biologics and raised the price target to HK$ 130.25 following a strong 1H26 earnings beat. - The positive rating is driven by robust product sales, expanding global presence, promising pipeline assets, and strategic alliances with Takeda and Pfizer. - These factors, alongside upcoming clinical and regulatory milestones, reinforce confidence in meeting management's long-term revenue targets for 2027 and 2030.WuXi Biologics: Upgraded Growth Outlook and Higher DCF-Based Target Price Support Buy Rating
Tip Ranks·- Wu Jing from China Securities has maintained a buy rating on WuXi Biologics while setting a target price of 60.00 HKD. - The rating is supported by strong 2026 first-half financial results, growing order backlogs, and upgraded multi-year revenue guidance from management. - Additional growth drivers include global capacity expansion, accelerated hiring, and the emerging biosimilar manufacturing business acting as a new profit pillar.